Antibody-producing immune cells can help shape cancer immunotherapy

Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why ...

A benchmark for antibodies: Open dataset aims to standardize sequencing and measurement

Antibodies are the immune system's precision tools for recognizing and neutralizing viruses, bacteria and other foreign ...

AI tools speed development of antibody probes to see activity inside living cells

Researchers at Colorado State University have determined how to use artificial intelligence to modify antibodies so they act ...
Yahoo Finance

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

WAYNE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for ...
Chromatography Online

Rapid Native HIC–MS Using Ammonium Tartrate for Robust Drug-to-Antibody Ratio Characterization of Antibody–Drug Conjugates

Genentech's native HIC-MS method uses ammonium tartrate, enabling efficient MS detection without compromising chromatographic ...
Mena FN

Aclaris Therapeutics Initiates Phase 1B Proof-Of-Concept Trial In Atopic Dermatitis (AD) With Its Novel Bispecific Antibody ATI-052

(MENAFN- GlobeNewsWire - Nasdaq) WAYNE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product ...
Finanznachrichten

Aclaris Therapeutics, Inc.: Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

WAYNE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for ...